Osha • Liang LLP
Combination therapy
This invention is directed to the use of SCD-1 inhibitors of the formula (I): where x, y, V, W, G, J, L, M, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein, in combination with other drug therapies to treat adverse weight gain.
Xenon Pharmaceuticals Inc.
A A A A A A A A A A A A A A A A A A A A A A
A61P A61P A61P A61K A61P A61P A61P A61P A61K A61P A61P A61P A61P A61P A61K A61P A61K A61P A61K A61P A61P A61P
inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
Rajender Serguei Mikhail Sultan Shaoyi Robert Sengen Mikhail A. Wenbao Chi Mark W. Kashinath Shifeng Heinz W. Mehran Seid Vishnumurthy Zaihui Michael D. Vandna Cindy J. Melwyn Jian-Min Daniel F. Nagasree Duanjie
Kamboj Sviridov Chafeev Chowdhury Sun Fraser Sun Kondratenko Li Tu Holladay Sadalapure Liu Gschwend Bagherzadeh Kodumuru Zhang Winther Raina Hudson Abreo Fu Harvey Chakka Hou